Du är här

2014-05-15

Cytokinetics, Inc.: Cytokinetics to Hold Annual Meeting of Stockholders

South San Francisco, CA., May 15, 2014 -

Cytokinetics, Incorporated (Nasdaq:CYTK) announced today that its Annual
Meeting of Stockholders will be held on Wednesday, May 21, 2014 at 3:00 PM
Pacific Time at the Embassy Suites Hotel, located at 250 Gateway Boulevard in
South San Francisco, CA. Robert I. Blum, President and Chief Executive
Officer, is scheduled to present an overview of Cytokinetics' performance.

Interested parties may access the live audio webcast of this presentation and
replay by visiting the Investor Relations section of the Cytokinetics website
at www.cytokinetics.com. The live conference call may also be accessed by
dialing (866) 999-CYTK (2985) (United States and Canada) or (706) 679-3078
(international) and typing in the passcode 46452054. The webcast will be
available via Cytokinetics' website for one week following the event. The
replay of the audiocast will be available via telephone from May 21, 2014 at
6:00 PM Pacific Time until May 28, 2014 by dialing (855) 859-2056 (United
States and Canada) or (404) 537-3406 (international) and typing in the
passcode 46452054.

About Cytokinetics

Cytokinetics is a clinical-stage biopharmaceutical company focused on the
discovery and development of novel small molecule therapeutics that modulate
muscle function for the potential treatment of serious diseases and medical
conditions. Cytokinetics' lead drug candidate from its cardiac muscle
contractility program,omecamtiv mecarbil
, is in Phase II clinical development for the potential treatment of heart
failure. Amgen Inc. holds an exclusive license worldwide to develop and
commercializeomecamtiv mecarbil
and related compounds, subject to Cytokinetics' specified development and
commercialization participation rights. Cytokinetics is independently
developingtirasemtiv
, a fast skeletal muscle activator, as a potential treatment for diseases and
medical conditions associated with neuromuscular dysfunction.Tirasemtiv
is the subject of a Phase II clinical trials program and has been granted
orphan drug designation and fast track status by the U.S. Food and Drug
Administration and orphan medicinal product designation by the European
Medicines Agency for the potential treatment of amyotrophic lateral sclerosis
(ALS). Cytokinetics is collaborating with Astellas Pharma Inc. to develop
CK-2127107, a skeletal muscle activator structurally distinct fromtirasemtiv
, for non-neuromuscular indications. All of these drug candidates have arisen
from Cytokinetics' muscle biology focused research activities and are
directed towards the cytoskeleton. The cytoskeleton is a complex biological
infrastructure that plays a fundamental role within every human cell.
Additional information about Cytokinetics can be obtained
atwww.cytokinetics.com.

This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics
disclaims any intent or obligation to update these forward-looking
statements, and claims the protection of the Act's safe harbor for
forward-looking statements. Examples of such statements include, but are not
limited to, statements relating to planned presentations, and the properties
and potential benefits of Cytokinetics' drug candidates and potential drug
candidates. Such statements are based on management's current expectations,
but actual results may differ materially due to various risks and
uncertainties, including, but not limited to, potential difficulties or
delays in the development, testing, regulatory approval and production of
Cytokinetics' drug candidates and potential drug candidates that could slow
or prevent clinical development or product approval, including risks that
current and past results of clinical trials or preclinical studies may not be
indicative of future clinical trials results and that Cytokinetics' drug
candidates and potential drug candidates may have unexpected adverse side
effects or inadequate therapeutic efficacy. For further information regarding
these and other risks related to Cytokinetics' business, investors should
consult Cytokinetics' filings with the Securities and Exchange Commission.

Contact:
Cytokinetics, Incorporated
Joanna L. Goldstein (Investors&Media)
(650) 624-3000

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cytokinetics, Inc. via Globenewswire

HUG#1785674

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.